David is a European and UK Patent Attorney. With 20 years' experience in the patent profession, David deals with a wide range of life science subject matter, including molecular biology, genetics, transgenic animals, immunology, vaccines, stem cells, and transgenic crop plants.
David has experience of filing and prosecuting patent applications in all major territories, particularly in Europe, the USA, Japan, Korea and Australia, but also in further-flung jurisdictions via experience of prosecution of some large patent families covering needleless injection, vaccine technology, and biopharmaceuticals that are now marketed drugs. He also helps coordinate foreign law information within J A Kemp on many countries.
He has also acts in oppositions and appeals before the European Patent Office, representing both patent proprietors and opponents. David's background is in genetics and his PhD and postdoctoral work related to gene targeting in mice so he has particular expertise regarding transgenic animals as models for human disease and research tools.
David's clients include large corporations, small and mid-size biotechnology companies in the UK, Japan and the USA.
David joined J A Kemp in 1999 and became a partner in 2009.